ContraFect Corporation

OTCPK:CFRX Stock Report

Market Cap: US$676.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ContraFect Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ContraFect.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth28.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated09 Nov 2023

Recent future growth updates

Recent updates

Seeking Alpha • Aug 15

Contrafect GAAP EPS of -$0.46 misses by $0.13

Contrafect press release (NASDAQ:CFRX): Q2 GAAP EPS of -$0.46 misses by $0.13. As of June 30, 2022, ContraFect had cash, cash equivalents and marketable securities of $27.3 million. Shares +4% PM
Seeking Alpha • Jul 13

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

Shares of micro-cap biotech ContraFect (NASDAQ:CFRX) plunged ~76% after hours as a data safety board recommended that the company's DISRUPT trial be stopped. The Data Safety and Monitoring Board (DSMB) recommended such an action "because the conditional power of the study was below the pre-specified threshold for futility," CFRX said in a statement on Wednesday. ContraFect's (CFRX) phase 3 DISRUPT trial was investigating the company's lysin exebacase in about 350 patients with complicated S. aureus bacteremia, which is the presence of the bacteria Staphylococcus aureus in the bloodstream. The DSMB's recommendation was based on an interim analysis of the clinical response rate of 84 patients in the trial at day 14, which was also the main goal of the study. "While further review of the data is ongoing, the company is initiating steps to notify investigators that patient enrollment in the trial is being stopped based on the DSMB recommendation," CFRX added.
Analysis Article • Jun 29

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Dec 25

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 15

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

CFRX is developing a medicine to treat bacterial infections without using an antibiotic. Phase 2 trials have shown outstanding data against MRSA infections, and reduced hospital time. The company has decent cash, but may need more.
Analysis Article • Aug 18

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 01

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 09

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

The big shareholder groups in ContraFect Corporation ( NASDAQ:CFRX ) have power over the company. Insiders often own a...
Analysis Article • Jan 15

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 24

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

A look at the shareholders of ContraFect Corporation (NASDAQ:CFRX) can tell us which group is most powerful...

Earnings and Revenue Growth Forecasts

OTCPK:CFRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/AN/AN/AN/A1
12/31/2024N/AN/AN/AN/A1
12/31/2023N/AN/AN/AN/A1
9/30/2023N/A-24-36-36N/A
6/30/2023N/A-36-37-37N/A
3/31/2023N/A-46-43-43N/A
12/31/2022N/A-65-46-46N/A
9/30/2022N/A-60-45-45N/A
6/30/2022N/A-48-46-46N/A
3/31/2022N/A-35-44-44N/A
12/31/2021N/A-20-41-41N/A
9/30/2021N/A-22-40-40N/A
6/30/2021N/A-14-37-37N/A
3/31/2021N/A-26-35-35N/A
12/31/2020N/A-28-33-33N/A
9/30/2020N/A-32-33-33N/A
6/30/2020N/A-41-29-29N/A
3/31/2020N/A-32-28-28N/A
12/31/2019N/A-13-27-27N/A
9/30/2019N/A3-27-27N/A
6/30/2019N/A4-29-29N/A
3/31/2019N/A-7-27-27N/A
12/31/2018N/A-38-26-26N/A
9/30/2018N/A-48-25-25N/A
6/30/2018N/A-46-25-25N/A
3/31/2018N/A-28-25-25N/A
12/31/2017N/A-16-25-25N/A
9/30/2017N/A-10-27-27N/A
6/30/2017N/A-19N/A-29N/A
3/31/2017N/A-26N/A-29N/A
12/31/2016N/A-29N/A-29N/A
9/30/2016N/A-37N/A-27N/A
6/30/2016N/A-32N/A-25N/A
3/31/2016N/A-29N/A-24N/A
12/31/2015N/A-25N/A-22N/A
9/30/2015N/A-22N/A-20N/A
6/30/2015N/A-33N/A-20N/A
3/31/2015N/A-34N/A-17N/A
12/31/2014N/A-35N/A-15N/A
9/30/2014N/A-41N/A-14N/A
6/30/2014N/A-29N/A-12N/A
3/31/2014N/A-24N/A-13N/A
12/31/2013N/A-24N/A-14N/A
9/30/2013N/A-19N/A-15N/A
6/30/2013N/A-20N/A-16N/A
3/31/2013N/A-20N/A-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CFRX's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if CFRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CFRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CFRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: CFRX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CFRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/04 20:34
End of Day Share Price 2023/12/04 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ContraFect Corporation is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBrean Capital Historical (Janney Montgomery)
Louise ChenCantor Fitzgerald & Co.
Keay NakaeChardan Capital Markets, LLC